World Allergy Organ J:辅助草变应原免疫治疗早期阶段临床响应的转录组分析和安全性情况

2019-12-18 AlexYang MedSci原创

特异性的免疫治疗是改善疾病治疗的唯一类型疗法,能够在季节过敏性鼻结膜炎快速的诱导去敏和维持长期的过敏原无响应状态。一种新的累积35600 SU Grass MATA MPL剂量的皮下免疫治疗方案的安全性和耐受性已经在预季节性,单盲和安慰剂I期临床研究中进行了评估。最近,研究人员通过外周血单核细胞转录组分析探索了潜在的免疫学机制。研究的受试者为中度到重度过敏性鼻炎或者鼻结膜炎(SAR),并以1:1的

特异性的免疫治疗是改善疾病治疗的唯一类型疗法,能够在季节过敏性鼻结膜炎快速的诱导去敏和维持长期的过敏原无响应状态。一种新的累积35600 SU Grass MATA MPL剂量的皮下免疫治疗方案的安全性和耐受性已经在预季节性,单盲和安慰剂I期临床研究中进行了评估。最近,研究人员通过外周血单核细胞转录组分析探索了潜在的免疫学机制。

研究的受试者为中度到重度过敏性鼻炎或者鼻结膜炎(SAR),并以1:1的比例随机分配到免疫治疗组和安慰剂对照组。研究发现,该免疫治疗方案对更高累积剂量具有良好的耐受性。基因表达情况与早期免疫相应相关,表明了先天和适应性免疫机制。通过IPA作图的途径和机制网络分析将差异表达的基因定位到了与T细胞分化、细胞因子信号通路和Th1/Th2激活通路相关的典型通路中。他们研究的转录组分析仍旧可以进行进一步的大规模研究,从而探索免疫治疗成功的预测标记。

最后,研究人员指出,更好剂量的35600 SU of Grass MATA MPL疫苗方案具有良好的耐受性和安全性。分子标记IL-27、IL-10、IL-4、TNF、IFNγ、TGFβ和TLR4是早期SIT治疗阶段主要的表达变化的预测分子驱使因子。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1654138, encodeId=450e1654138d7, content=<a href='/topic/show?id=98f4933e0cd' target=_blank style='color:#2F92EE;'>#转录组分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93370, encryptionId=98f4933e0cd, topicName=转录组分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07e724453575, createdName=zhangyxzsh, createdTime=Mon Aug 24 11:40:00 CST 2020, time=2020-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747381, encodeId=32bf1e4738175, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Thu Sep 10 16:40:00 CST 2020, time=2020-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329316, encodeId=b0d1132931687, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Fri Dec 20 14:40:00 CST 2019, time=2019-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420195, encodeId=e1fb1420195e1, content=<a href='/topic/show?id=5f3a9336904' target=_blank style='color:#2F92EE;'>#转录组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93369, encryptionId=5f3a9336904, topicName=转录组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c9e3571203, createdName=marlenexl, createdTime=Fri Dec 20 14:40:00 CST 2019, time=2019-12-20, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1654138, encodeId=450e1654138d7, content=<a href='/topic/show?id=98f4933e0cd' target=_blank style='color:#2F92EE;'>#转录组分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93370, encryptionId=98f4933e0cd, topicName=转录组分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07e724453575, createdName=zhangyxzsh, createdTime=Mon Aug 24 11:40:00 CST 2020, time=2020-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747381, encodeId=32bf1e4738175, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Thu Sep 10 16:40:00 CST 2020, time=2020-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329316, encodeId=b0d1132931687, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Fri Dec 20 14:40:00 CST 2019, time=2019-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420195, encodeId=e1fb1420195e1, content=<a href='/topic/show?id=5f3a9336904' target=_blank style='color:#2F92EE;'>#转录组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93369, encryptionId=5f3a9336904, topicName=转录组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c9e3571203, createdName=marlenexl, createdTime=Fri Dec 20 14:40:00 CST 2019, time=2019-12-20, status=1, ipAttribution=)]
    2020-09-10 mjldent
  3. [GetPortalCommentsPageByObjectIdResponse(id=1654138, encodeId=450e1654138d7, content=<a href='/topic/show?id=98f4933e0cd' target=_blank style='color:#2F92EE;'>#转录组分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93370, encryptionId=98f4933e0cd, topicName=转录组分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07e724453575, createdName=zhangyxzsh, createdTime=Mon Aug 24 11:40:00 CST 2020, time=2020-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747381, encodeId=32bf1e4738175, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Thu Sep 10 16:40:00 CST 2020, time=2020-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329316, encodeId=b0d1132931687, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Fri Dec 20 14:40:00 CST 2019, time=2019-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420195, encodeId=e1fb1420195e1, content=<a href='/topic/show?id=5f3a9336904' target=_blank style='color:#2F92EE;'>#转录组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93369, encryptionId=5f3a9336904, topicName=转录组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c9e3571203, createdName=marlenexl, createdTime=Fri Dec 20 14:40:00 CST 2019, time=2019-12-20, status=1, ipAttribution=)]
    2019-12-20 膀胱癌
  4. [GetPortalCommentsPageByObjectIdResponse(id=1654138, encodeId=450e1654138d7, content=<a href='/topic/show?id=98f4933e0cd' target=_blank style='color:#2F92EE;'>#转录组分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93370, encryptionId=98f4933e0cd, topicName=转录组分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07e724453575, createdName=zhangyxzsh, createdTime=Mon Aug 24 11:40:00 CST 2020, time=2020-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747381, encodeId=32bf1e4738175, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Thu Sep 10 16:40:00 CST 2020, time=2020-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329316, encodeId=b0d1132931687, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Fri Dec 20 14:40:00 CST 2019, time=2019-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420195, encodeId=e1fb1420195e1, content=<a href='/topic/show?id=5f3a9336904' target=_blank style='color:#2F92EE;'>#转录组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93369, encryptionId=5f3a9336904, topicName=转录组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c9e3571203, createdName=marlenexl, createdTime=Fri Dec 20 14:40:00 CST 2019, time=2019-12-20, status=1, ipAttribution=)]

相关资讯

Asian Pac J Allergy Immunol:高风险阻塞性睡眠呼吸暂停在过敏性鼻炎患者中的患病率研究

尽管过敏性鼻炎(AR)还没有被承认是阻塞性睡眠呼吸暂停(OSA)的一个风险因子,但两者之间的一些病理生理联系却有很多的报道。然而,OSA在AR患者中的流行病学数据仍旧缺乏。最近,有研究人员调查了AR患者中高风险OSA的患病率情况,并确定了OSA与AR严重度之间的关系。研究人员招募了年龄大于18岁且诊断为AR的患者,时间为2014年10月到2015年11月。研究共包括了120名AR患者(45名男性,

Int Arch Allergy Immunol:鼻腔炎症疾病学龄前儿童鼻一氧化氮浓度的临床意义研究

过敏性鼻炎是鼻呼吸道的一种过敏性炎症,并且慢性鼻窦炎是鼻窦炎症疾病。该疾病可以通过感染、过敏或者自身免疫问题诱导产生。这两种疾病的诊断主要是通过临床症状,过敏原测试和成像来诊断。过敏原测试是非侵入的但较为昂贵。成像测试对儿童来讲较为困难。鼻一氧化氮(NNO)的测量时非侵入的,且没有辐射,花费较少。最近,有研究人员评估了NNO在鼻炎症疾病学龄前儿童中的临床意义。研究包括了55名过敏性鼻炎儿童,包括了

Ann Allergy Asthma Immunol:奥洛他定-莫米松组合鼻喷雾对季节过敏性鼻炎治疗效果和安全性研究

GSP301是试验用固定剂量的盐酸奥洛他定(抗组胺药)和糠酸莫米松(皮质类固醇)组合鼻喷雾。最近,有研究人员评估了GSP301对季节性AR(SAR)患者的治疗效果和安全性情况。研究是一个2期、双盲和平行组研究,SAR患者(不小于12岁)随机的分配到不同的药物组合和用量组中。研究共包括了1111名患者。研究发现,与安慰剂对照组(p<0.001)、一日两次奥洛他定治疗(p=0.049)和莫米松治

Pediatr Allergy Immunol:季节过敏性鼻炎儿童和成年鼻分泌物中lgE抗体谱分析

鼻分泌物(NS)中测试lgE和季节过敏性鼻炎(SAR)的分子诊断越来越流行。然而,最新分子试验进行的鼻lgE检测的可靠性还未在一个大的花粉过敏性患者群体中评估。最近,有研究人员利用显微镜技术,在一个大的SAR儿童和成年人群体中调查和比较了NS和血清中特异性lgE(slgE)抗体谱情况。研究人员在90名儿童和71名成年人SAR患者中采集了样本,并在NS和血清中测量了112种过敏原分子的总lgE和sl

盘点:近期鼻炎盘点

鼻炎即鼻腔炎性疾病,是病毒、细菌、变应原、各种理化因子以及某些全身性疾病引起的鼻腔黏膜的炎症。鼻炎的主要病理改变是鼻腔黏膜充血、肿胀、渗出、增生、萎缩或坏死等。梅斯医学小编整理了近期鼻炎的研究进展,与大家一起分享学习!【1】Int Forum Allergy Rhinol:非囊性纤维化性支气管扩张患者的慢性鼻窦炎的患病率和鉴定 https://www.ncbi.nlm.nih.gov/pu

盘点:鼻炎治疗进展盘点

【1】Immunotherapy:舌下免疫治疗对屋尘螨诱导的过敏性鼻炎和并发症的疗效分析 https://www.ncbi.nlm.nih.gov/pubmed/31608757最近,有研究人员调查了舌下免疫治疗对尘螨诱导的过敏性鼻炎和其过敏性并发症的影响。研究是一个前瞻性的案例对照研究,包括了120名患者(案例80,对照40),调查持续的时间为12个月。研究发现,舌下免疫治疗能够在尘螨诱